Creative Medical Technology Holdings (CELZ) Non-Current Assets (2016 - 2026)
Creative Medical Technology Holdings' (CELZ) quarterly Non-Current Assets came in at $358740.0 in Q2 2026, down 24.08% year-over-year from $472521.0 in Q2 2025, and down 6.0% quarter-over-quarter from $381658.0 in Q1 2026.
Analysis
Creative Medical Technology Holdings (CELZ) Non-Current Assets (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Non-Current Assets for 11 consecutive years, with $358740.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 24.08% year-over-year to $358740.0 in Q2 2026; TTM through Jun 2026 was $1.6 million, a 22.93% decrease from a year earlier, with the FY2025 full-year figure at $410511.0, down 23.1% from the prior year.
- Non-Current Assets was $358740.0 for Q2 2026 at Creative Medical Technology Holdings, down from $381658.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $556479.0 in Q3 2024 and troughed at $358740.0 in Q2 2026.
- A 5-year average of $448648.3 and a median of $442877.0 in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets grew 22.49% in 2025 and decreased 24.16% in 2026, its largest moves.
- Over 5 years, Non-Current Assets stood at $438876.0 in 2022, then grew by 1.23% to $444292.0 in 2023, then rose by 20.16% to $533840.0 in 2024, then declined by 23.1% to $410511.0 in 2025, then retreated by 12.61% to $358740.0 in 2026.
- The last three Non-Current Assets figures came in at $358740.0 (Q2 2026), $381658.0 (Q1 2026), and $410511.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 441.00 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | 279.00 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 451.27 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 523.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 150.83 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 207.76 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 35.91 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 964.69 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 238.14 Mn |
| 10 | Creative Medical Technology Holdings | 1.48 Mn | 1.50 Mn | - | 358,740.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 358,740.00 |
| Mar 31, 2026 | 381,658.00 |
| Dec 31, 2025 | 410,511.00 |
| Sep 30, 2025 | 441,462.00 |
| Jun 30, 2025 | 472,521.00 |
| Mar 31, 2025 | 503,263.00 |
| Dec 31, 2024 | 533,840.00 |
| Sep 30, 2024 | 556,479.00 |
| Jun 30, 2024 | 385,750.00 |
| Mar 31, 2024 | 415,021.00 |
| Dec 31, 2023 | 444,292.00 |
| Sep 30, 2023 | 469,813.00 |
| Jun 30, 2023 | 392,834.00 |
| Mar 31, 2023 | 415,855.00 |
| Dec 31, 2022 | 438,876.00 |
| Sep 30, 2022 | 461,897.00 |
| Jun 30, 2022 | 484,918.00 |
| Mar 31, 2022 | 507,939.00 |
| Dec 31, 2021 | 530,960.00 |
| Sep 30, 2021 | 553,982.00 |